Showing all 3 results
Fulvestrant Injection
FreeProduct Composition & Strength
We supply this product as a Sterile Oily Solution in Prefilled Syringes (PFS) or Vials. (Note: This is a high-viscosity injection).
Active Ingredient Strength Volume Fulvestrant USP/BP 250 mg 5 ml Prefilled Syringe (50 mg/ml) Fulvestrant USP/BP 250 mg 5 ml Vial (50 mg/ml) Vehicle Castor Oil / Benzyl Alcohol Viscous Oily Base *Pack Sizes: Box of 1 PFS (with safety needles) or Box of 2 PFS (for 500mg dose).
Tamoxifen Citrate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-PVC or opaque Alu-Alu blister strips to preserve the integrity of the highly sensitive hormonal API.
Active Ingredient Strength Primary Clinical Use Tamoxifen Citrate USP/Ph.Eur. 10 mg (Equivalent to Tamoxifen Base) Standard divided-dose therapy and specific prophylactic risk-reduction protocols. Tamoxifen Citrate USP/Ph.Eur. 20 mg (Equivalent to Tamoxifen Base) Global Standard: Target once-daily adult maintenance dose for ER+ breast cancer. Excipients Mannitol / Maize Starch / Magnesium Stearate / Croscarmellose Sodium Diluent / Superdisintegrant (Engineered for immediate gastric dispersion and reliable absorption) Tamoxifen Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Uncoated or Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-PVC or opaque Alu-Alu blister strips to preserve the integrity of the highly sensitive hormonal API.
Active Ingredient Strength Primary Clinical Use Tamoxifen Citrate USP/Ph.Eur. 10 mg Standard divided-dose therapy and specific risk-reduction protocols. Tamoxifen Citrate USP/Ph.Eur. 20 mg Global Standard: Target once-daily adult maintenance dose for ER+ breast cancer. Excipients Mannitol / Maize Starch / Magnesium Stearate / Croscarmellose Sodium Diluent / Superdisintegrant (Engineered for immediate gastric dispersion and reliable absorption)
